Cipher Pharmaceuticals Inc.
TSX:CPH.TODrug Manufacturers - Specialty & Generic
+$0.15 today
- Market cap
- $331.67M
- Beta
- 0.48
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.22
Volume 0.04M
Average 0.03M
CPH.TO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Cipher Pharmaceuticals Inc.TSX: CPH.TO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q1 FY2026 EBITDA of $7.28M rose 69.5% year over year, behind the +96.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 70.6% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.
Context
- EBITDA amounted to 46.9% of revenue in FY2025, up 11.4 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of $33.01M (+37.0%) for the fiscal year ending Dec 2026, a slowdown from the +103.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.28M+70.6% QoQ
- Last fiscal yearDec 2025
- $24.1M+103.1% YoY
- LTMMar 2026
- $25.12M+96.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +69.5% | +9.3% | -60.2 pp |
| 1 year | +103.1% | +37.0% | -66.1 pp |
| 3-year CAGR | +26.0% | +1.9% | -24.2 pp |
| 5-year CAGR | +2.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 24.1M USD
- Year-over-year change
- +103.1%
- 4-year CAGR
- +15.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.1M | +103.1% |
| FY2024 | 2024-12-31 | 11.87M | +2.9% |
| FY2023 | 2023-12-31 | 11.53M | -4.2% |
| FY2022 | 2022-12-31 | 12.04M | -11.9% |
| FY2021 | 2021-12-31 | 13.66M | — |
EBITDA vs competitors
How CPH.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +96.0% is the 2nd highest of 8, against a peer median of -6.0%.
- EBITDA amounts to 49.3% of revenue for CPH.TO, versus a peer median of 14.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$65.18M CAD | -6.0% | +29.1% | 12.8% | |
| LTM Mar 2026 | $60.46M USD | +510.4% | — | 23.1% | |
| LTM Mar 2026 | $25.12M USD | +96.0% | +26.0% | 49.3% | |
| LTM Mar 2026 | CA$9.82M CAD | -80.9% | — | 3.1% | |
| LTM Mar 2026 | -$5.36M USD | +48.2% | — | 10.5% | |
| LTM Mar 2026 | -CA$35.21M CAD | -81.6% | — | 1275.3% | |
| LTM Mar 2026 | -CA$40.84M CAD | -681.4% | — | 14.9% | |
| LTM Mar 2026 | -CA$63.48M CAD | +86.8% | — | 20.4% | |
| Peer median (excluding CPH.TO) | — | -6.0% | +29.1% | 14.9% | |
Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 21.94M | 20.68M | 21.16M | 33.36M | 51.33M |
| Cost of Revenue | 3.68M | 3.99M | 4.07M | 9.26M | 17.56M |
| Gross Profit | 18.26M | 16.68M | 17.09M | 24.1M | 33.77M |
| Gross Margin | 83.2% | 80.7% | 80.8% | 72.2% | 65.8% |
| Research & Development | 88K | 98K | 139K | 0 | 21.37K |
| Selling, General & Admin | 5.11M | 4.4M | 5.43M | 12.24M | 16.3M |
| Operating Expenses | 6.45M | 5.63M | 5.56M | 16.26M | 16.97M |
| Depreciation & Amortization | 701K | 989K | 1.23M | 4.02M | 7.23M |
| EBITDA | 13.66M | 12.04M | 11.53M | 11.87M | 24.1M |
| EBITDA Margin | 62.2% | 58.2% | 54.5% | 35.6% | 46.9% |
| Operating Income | 11.82M | 12.04M | 11.53M | 7.85M | 16.8M |
| Operating Margin | 53.9% | 58.2% | 54.5% | 23.5% | 32.7% |
| Interest Income | 12K | 464K | 1.87M | 330K | 0 |
| Interest Expense | 92K | 0 | 0 | 0 | 1.19M |
| Other Income / Expenses | (2M) | (560K) | 1.15M | (4.89M) | 661.38K |
| Income Before Tax | 11.06M | 11.48M | 12.68M | 2.96M | 17.46M |
| Pre-Tax Margin | 50.4% | 55.5% | 59.9% | 8.9% | 34.0% |
| Income Tax Expense | 3.3M | (15.16M) | (7.7M) | (8.59M) | (10.34M) |
| Net Income | 7.76M | 26.64M | 20.38M | 11.55M | 27.81M |
| Net Margin | 35.4% | 128.8% | 96.3% | 34.6% | 54.2% |
| EPS (Basic) | 0.29 | 1.06 | 0.80 | 0.47 | 1.09 |
| EPS (Diluted) | 0.29 | 1.04 | 0.80 | 0.47 | 1.07 |
| Weighted Avg Shares | 26.6M | 25.13M | 25.48M | 24.72M | 25.48M |
| Weighted Avg Shares (Diluted) | 26.83M | 25.59M | 25.42M | 24.57M | 25.99M |
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
Intrinsic Alpha fair value
Locked
Current Price
$13.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.